Mexifin ampoules 50mg/ml 2ml №10

Mexifin

Ethyl methyl hydroxypyridine succinate

2-ethyl-6-methyl-3-hydroxypyridine succinate

Dosage form

solution for intravenous and intramuscular administration

Composition

Active substance - ethylmethylhydroxypyridine succinate - 50 mg
Auxiliary substance - water for injections - to volume of 1 ml

Colorless or slightly colored clear liquid.

Antioxidant agent.

- N07ХХ.

Pharmacology

Mexifin belongs to the group of compounds of 3-hydroxypyridine and succinic acid and has antioxidant, antihypoxic, membrane stabilizing, nootropic, protective, anticonvulsant and anxiolytic effects.

Mexifin acts as an inhibitor of free radicals, inhibits lipid peroxidation, increases the activity of the antioxidant system of enzymes, restores the structure and function of membranes disturbed in various pathologies, has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholine disterase),receptor complexes, including benzodiazepine, GABA, acetylcholine; improves neurotransmitter transport, synaptic transmission and interrelation of brain structures. Increases the content in the brain dopamine.

The mechanism of action of mexifin is due to its ability to enhance the compensatory activation of aerobic glycolysis. It reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, increasing the content of ATP and creatine phosphate; contributes to the preservation of the structural and functional organization of biomembranes.

Mexifin improves brain metabolism and blood supply to the brain, corrects disorders in the regulatory and microcirculatory systems, suppressing constriction of arterioles and precapillaries; improves the rheological properties of blood, reducing platelet aggregation, stabilizing the membrane structure of blood cells (erythrocytes and platelets), preventing hemolysis; improves the immune system. Mexifin has an anti-atherogenic effect, causing regression of atherosclerotic changes in the arteries, reducing cholesterol and low-density lipoproteins, restoring lipid homeostasis.

Mexifin increases the performance and resistance of the body to the effects of various extreme damaging factors in oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebral circulation disorders, physical and mental overload), alcohol intoxication and antipsychotics (neuroleptics).

With a single and course application of mexifin, the maximum plasma concentration is reached in 0.45 -0.5 hours. When administered in a dose of 400-500 mg Cmax in the blood plasma - 3.5-4 μg / ml. With intramuscular administration of the drug is determined in the blood plasma for 4 hours. Pharmacokinetic profiles do not differ significantly with both single and continuous administration. Excreted from the body with urine mainly in the form of glucurononjugates and in small quantities in unchanged form.

Indications and usage

• acute disorders of cerebral circulation (as part of combination therapy);
• encephalopathy;
• vegetative vascular dystonia;
• mild cognitive impairment of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like conditions;
• relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• acute intoxication with antipsychotics.

Contraindications

Acute disorders of the liver and kidneys, increased individual sensitivity to the drug.
Children's age, pregnancy, breastfeeding - due to insufficient study of the drug in these categories of patients.

Dosage and administration

Mexifin prescribed intramuscularly or intravenously (jet or drip). Doses are selected individually.The duration of treatment and dosing regimen depends on the severity of the patient's condition and the effectiveness of treatment. Begin treatment with a dose of 50 - 100 mg 1-3 times a day, gradually increasing the dose to obtain a therapeutic effect. The maximum daily dose should not exceed 800 mg. When the infusion method of administration of the drug should be diluted in physiological sodium chloride solution.

Jet mexifin slowly injected for 5-7 minutes; drip - at a rate of 60 drops per minute.

Acute disorders of cerebral circulation: as part of combination therapy, intravenously drip 200-300 mg in the first 2-4 days, then intramuscularly in 100 mg 3 times a day. Course duration is 10-14 days.

Dyscirculatory encephalopathy (decompensation phase): intravenous bolus or drip 100 mg 2-3 times a day for 14 days, then intramuscularly at 100 mg per day for the next 14 days.

Prevention of circulatory encephalopathy: intramuscularly on 100 mg 2 times a day for 10-14 days.

Mild cognitive impairment in elderly patients and in anxiety disorders: intramuscularly 100 to 300 mg per day for 14-30 days. Alcohol withdrawal syndrome: 100 - 200 mg intramuscularly 2-3 times a day or intravenously drip 1 -2 times a day for 5-7 days.

Acute neuroleptic intoxication: intravenously 50-300 mg per day for 7-14 days, depending on the severity of the condition.

When neurotic disorders and vegetative-vascular dystonia, the drug is administered intramuscularly at a dose of 50-400 mg per day for 14 days.

Adverse reactions

The appearance of individual adverse reactions is possible: nausea and dry mouth; drowsiness; allergic reactions are possible.

Drug interactions

Potentiates the action of benzodiazepine anxiolytics, anticonvulsants and anti-parkinsonian drugs. The drug reduces the toxic effects of ethyl alcohol.

Special notes

At the beginning of drug treatment, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration of attention and psychomotor speed. Currently, a number of drugs with the same active ingredient ethylmethylhydroxypyridine nosinat are being produced, which should be considered when treating other diseases, in the treatment of which drugs with this substance can be used.

Overdosage

Overdose may cause drowsiness.

Solution for intravenous and intramuscular administration of 50 mg / ml. Ampoules 2ml or 5ml. 5 or 10 ampoules are placed in a blister packaging. On 1 or 2 blister strip packagings together with the instruction for a medical use in a cardboard pack.

Storage conditions

List B. Store in a dry, protected from light, out of reach of children, at a temperature not higher than 25 ° C.